Prosecution Insights
Last updated: October 02, 2026
Application No. 18/680,822

SYNTHESIS AND PREPARATION OF ULTRA-LOW VISCOSITY AND HIGH MAGNETIC SUSCEPTIBILITY MAGNETIC IONIC LIQUIDS

Non-Final OA §112
Filed
May 31, 2024
Priority
Jun 01, 2023 — provisional 63/505,464
Examiner
RILEY, JEZIA
Art Unit
Tech Center
Assignee
Iowa State University Research Foundation Inc.
OA Round
1 (Non-Final)
83%
Grant Probability
Favorable
1-2
OA Rounds
1m
Est. Remaining
90%
With Interview

Examiner Intelligence

Grants 83% — above average
83%
Career Allowance Rate
1094 granted / 1319 resolved
+22.9% vs TC avg
Moderate +7% lift
Without
With
+7.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 5m
Avg Prosecution
34 currently pending
Career history
1334
Total Applications
across all art units

Statute-Specific Performance

§101
2.5%
-37.5% vs TC avg
§103
26.6%
-13.4% vs TC avg
§102
24.8%
-15.2% vs TC avg
§112
21.9%
-18.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1319 resolved cases

Office Action

§112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Election/Restrictions Applicant's election with traverse of Group I in the reply filed on 09/03/2026 is acknowledged. The traversal is on the ground(s) that examination of all claims can be made without serious burden. This is not found persuasive because (a) the inventions have acquired a separate status in the art in view of their different classification; (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter; (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries); (d) the prior art applicable to one invention would not likely be applicable to another invention; and/or (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph. The requirement is still deemed proper and is therefore made FINAL. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claims 1-2 are vague and indefinite because in the phrases “wherein the metal comprises nickel (Ni), copper (Cu), cobalt (Co), iron (Fe), manganese (Mn), chromium (Cr), vanadium (V), dysprosium (Dy), holmium (Ho), gadolinium (Gd), neodymium (Nd), europium (Eu), cerium (Ce), thulium (Tm), ruthenium (Re), terbium (Tb), erbium (Er), ytterbium (Yb), and a salt or a mixture thereof” and “wherein M comprises nickel (Ni), copper (Cu), cobalt (Co), iron (Fe), manganese (Mn), chromium (Cr), vanadium (V), dysprosium (Dy), holmium (Ho), gadolinium (Gd), neodymium (Nd), europium (Eu), cerium (Ce), thulium (Tm), ruthenium (Re), terbium (Tb), erbium (Er), ytterbium (Yb), and salts or mixtures thereof”, the word “comprises” makes it unclear if the metal or M is a combination of all the metals and salt, or if the metal is selected from the list of metals and salt and the mixture thereof. It is suggested to amend the claims as follow: “wherein the metal is selected from the group consisting of nickel (Ni), copper (Cu), cobalt (Co), iron (Fe), manganese (Mn), chromium (Cr), vanadium (V), dysprosium (Dy), holmium (Ho), gadolinium (Gd), neodymium (Nd), europium (Eu), cerium (Ce), thulium (Tm), ruthenium (Re), terbium (Tb), erbium (Er), ytterbium (Yb), salt thereof and a mixture thereof”, or “wherein the metal comprises nickel (Ni), copper (Cu), cobalt (Co), iron (Fe), manganese (Mn), chromium (Cr), vanadium (V), dysprosium (Dy), holmium (Ho), gadolinium (Gd), neodymium (Nd), europium (Eu), cerium (Ce), thulium (Tm), ruthenium (Re), terbium (Tb), erbium (Er), ytterbium (Yb), a salt thereof, or a mixture thereof”. “wherein M is selected from the group consisting of nickel (Ni), copper (Cu), cobalt (Co), iron (Fe), manganese (Mn), chromium (Cr), vanadium (V), dysprosium (Dy), holmium (Ho), gadolinium (Gd), neodymium (Nd), europium (Eu), cerium (Ce), thulium (Tm), ruthenium (Re), terbium (Tb), erbium (Er), ytterbium (Yb), a salt thereof, and a mixture thereof”, or “wherein M comprises nickel (Ni), copper (Cu), cobalt (Co), iron (Fe), manganese (Mn), chromium (Cr), vanadium (V), dysprosium (Dy), holmium (Ho), gadolinium (Gd), neodymium (Nd), europium (Eu), cerium (Ce), thulium (Tm), ruthenium (Re), terbium (Tb), erbium (Er), ytterbium (Yb), a salt thereof or a mixture thereof”. In claim 1 the term "substituted" is recited for the R10 and R11 groups and is vague and indefinite because it is unclear of exactly what type of substituent moieties are used. Claim 2 is vague and indefinite because the first two structures for the anionic ligand comprise R–(CO)-CH2-O-CH2-(CO)-R. However, the anionic ligand as claimed in claim 1 comprises a carbanion not an oxygen atom (see general formula (III)). Therefore, there is insufficient antecedent basis for this limitation in the claim. Claim 3 is vague and indefinite because it is unclear what “C₆-DGE, C8-DGE, cyclo-C₆-DGE, and furan-C8-DGE” stand for. DGE should be spelled out for more clarity. Note that although the claims are interpreted in light of the specification, limitations from the specification are not read into the claims. Also see In re Van Geuns, 988 F.2d 1181,26 USPQ2d 1057 (Fed. Cir. 1993). Also see, In re Zetz, 13 USPQ2d 1320,1322. “An essential purpose of patent examination is to fashion claims that are precise, clear, correct and unambiguous.” Any inquiry concerning this communication or earlier communications from the examiner should be directed to JEZIA RILEY whose telephone number is (571)272-0786. The examiner can normally be reached 7:30-6:00pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at 571-272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /JEZIA RILEY/Primary Examiner, Art Unit 1681 19 September 2026
Read full office action

Prosecution Timeline

May 31, 2024
Application Filed
Sep 23, 2026
Non-Final Rejection mailed — §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12735733
LABELLING OF BIOMOLECULES
4y 6m to grant Granted Sep 15, 2026
Patent 12728098
METHODS OF PRODUCING EXTRACELLULAR VESICLES
4y 5m to grant Granted Sep 08, 2026
Patent 12716093
METHODS AND COMPOSITIONS RELATING TO CONTINUOUS SEQUENCING
3y 10m to grant Granted Aug 25, 2026
Patent 12709772
NON-AMPLIFIABLE POLYNUCLEOTIDES FOR ENCODING INFORMATION
4y 4m to grant Granted Aug 18, 2026
Patent 12703881
METHOD FOR LABELING NUCLEIC ACID
3y 5m to grant Granted Aug 11, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
83%
Grant Probability
90%
With Interview (+7.3%)
2y 5m (~1m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1319 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month